Evidence map›Paper›PMID 38587534›Full record

ArticleCardiovascular and interventional radiology2024

Quality of Life Analysis of Patients Treated with Percutaneous Hepatic Perfusion for Uveal Melanoma Liver Metastases.

T M L Tong, M Fiocco, J J van Duijn-de Vreugd, J Lutjeboer, F M Speetjens, F G J Tijl, M E Sitsen, R W M Zoethout, C H Martini, A L Vahrmeijer and 5 more

Erratum issuedAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cardiovascular and interventional radiology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

15 authors.

T M L TongInterventional Radiology Research (IR2) Group, Department of Radiology, C2-S, Leiden University Medical Center, Albinusdreef 2, 2333 ZA, Leiden, The Netherlands.ORCID http://orcid.org/0000-0002-7381-6858
M FioccoMathematical Institute, Leiden University, Leiden, The Netherlands.
J J van Duijn-de VreugdInterventional Radiology Research (IR2) Group, Department of Radiology, C2-S, Leiden University Medical Center, Albinusdreef 2, 2333 ZA, Leiden, The Netherlands.
J LutjeboerInterventional Radiology Research (IR2) Group, Department of Radiology, C2-S, Leiden University Medical Center, Albinusdreef 2, 2333 ZA, Leiden, The Netherlands.
F M SpeetjensDepartment of Medical Oncology, Leiden University Medical Center, Leiden, The Netherlands.
F G J TijlDepartment of Extra Corporal Circulation, Leiden University Medical Center, Leiden, The Netherlands.
M E SitsenDepartment of Anesthesiology, Leiden University Medical Center, Leiden, The Netherlands.
R W M ZoethoutDepartment of Anesthesiology, Leiden University Medical Center, Leiden, The Netherlands.
C H MartiniDepartment of Anesthesiology, Leiden University Medical Center, Leiden, The Netherlands.
A L VahrmeijerDepartment of Surgery, Leiden University Medical Center, Leiden, The Netherlands.
R W van der MeerInterventional Radiology Research (IR2) Group, Department of Radiology, C2-S, Leiden University Medical Center, Albinusdreef 2, 2333 ZA, Leiden, The Netherlands.
C S P van RijswijkInterventional Radiology Research (IR2) Group, Department of Radiology, C2-S, Leiden University Medical Center, Albinusdreef 2, 2333 ZA, Leiden, The Netherlands.
A R van ErkelInterventional Radiology Research (IR2) Group, Department of Radiology, C2-S, Leiden University Medical Center, Albinusdreef 2, 2333 ZA, Leiden, The Netherlands.
E KapiteijnDepartment of Medical Oncology, Leiden University Medical Center, Leiden, The Netherlands.
M C BurgmansInterventional Radiology Research (IR2) Group, Department of Radiology, C2-S, Leiden University Medical Center, Albinusdreef 2, 2333 ZA, Leiden, The Netherlands. M.C.Burgmans@lumc.nl.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposePercutaneous hepatic perfusion with melphalan (M-PHP) is a minimally invasive therapy with proven efficacy in patients with uveal melanoma (UM) liver metastases. M-PHP is associated with a short hospital admission time and limited systemic side effects. In this study, we assessed quality of life (QoL) in UM patients treated with M-PHP. MATERIALS AND

methodsA prospective, single-center study including 24 patients treated with M-PHP for UM metastases to the liver. QoL questionnaires were collected at baseline, on day 2/3 after M-PHP, and on day 7 and day 21 after M-PHP, according to study protocol. The results were scored according to EORTC-QLQ C30 global health status (GHS), functional scales, and symptom scales. The difference in scores at baseline and subsequent time points was analyzed with the Wilcoxon signed-rank test and multiple testing Bonferroni correction. Adverse events (AE) were registered up to 30 days after M-PHP according to CTCAE v5.0.

resultsTwenty-four patients (14 males; median age 63.0 years) completed 96 questionnaires. Most scores on all scales declined on day 2/3 after M-PHP. On day 21 after M-PHP, 12 out of 15 scores returned to baseline, including median GHS scores. Three variables were significantly worse on day 21 compared to baseline: fatigue (6-33; p = 0.002), physical functioning (100 vs 86.7; p = 0.003), and role functioning (100 vs 66.7; p = 0.001). Grade 3/4 AEs consisted mainly of hematological complications, such as leukopenia and thrombopenia.

conclusionM-PHP causes fatigue and a decline in physical and role functioning in the 1st weeks after treatment, but GHS returns to baseline levels within 21 days. LEVEL OF EVIDENCE 3: Cohort study.

Indexed as

Liver NeoplasmsMelanomaMelphalanQuality of LifeUveal NeoplasmsAdultAgedAntineoplastic Agents, AlkylatingChemotherapy, Cancer, Regional PerfusionFemaleHumansMaleMiddle AgedProspective StudiesSurveys and QuestionnairesTreatment OutcomeAntineoplastic Agents, AlkylatingMelphalanChemotherapyLiver metastasesMelphalanPercutaneous hepatic perfusionUveal melanoma

Identifiers

PMID38587534
PMCPMC11164794

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.